55092
| Phase IB-II, open label, multicentre feasibility study of Pazopanib in combination with Paclitaxel and Carboplatin in patients with platinum-refractory/resistant ovarian, fallopian tube or peritoneal carcinoma. |
55102
| A phase III Trial of postoperative chemotherapy or no further treatment for patients with stage I-II medium or high risk endometrial cancer. |
55051
| A multi-national randomized Phase III GCIG Intergroup Study comparing Pegylated Liposomal Doxorubicin and Carboplatin (CaC) versus Paclitaxel and Carboplatin (TC) in patients with epithelial ovarian cancer in late relapse (>6 months). |
55041
| A randomized, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I and Stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer |
55984
| A randomized trial of Adryamicin (A) Cisplatin (P) chemotherapy versus Paclitaxel (T) Adriamycin (A) and Cisplatin (P) in patients with metastatic/relapsed or locally advanced inoperable endometrial cancer. |
55012
| A phase III study of Cisplatin plus Topotecan followed by Paclitaxel plus Carboplatin versus Paclitaxel plus Carboplatin as first line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer. |
55994
| Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs.
concomitant radiotherapy and chemotherapy in
FIGO Ib2, IIa > 4 cm or IIb cervical cancer. |
55961
| EORTC 55961,Phase II study on Paclitaxel in recurrent uterine
papillary serous carcinoma (UPSC) |
55005
| A randomized phase III study comparing Gemcitabine plus Carboplatin versus Carboplatin monotherapy in patients with advanced eepithelial ovarian carcinoma who failed first-line platinum based therapy
Intergroup AGO-EORTC-NCIC CTG trial (EORTC 55005)
|
55985
| PHASE II CLINICAL TRIAL ON TAXOL AS SINGLE AGENT
IN LOCALLY ADVANCED AND/OR METASTATIC OR RECURRENT
VULVA CANCER NOT AMENABLE FOR
SURGERY AND/OR RADIOTHERAPY - EORTC trial 55985 |
55963
| A randomized phase III study for the treatment of recurrent epithelial ovarian cancer:
Chemotherapy alone versus chemotherapy followed by secondary cytoreductive
surgery in patients with a treatment-free interval
of more than 12 months-trial 55963
|
55991
| A randomized trial of adjuvant treatment with radiation plus chemotherapy versus radiation alone in high risk endometrial carcinoma.
|
55981
| A randomized trial of Paclitaxel/Epirubicin/Carboplatin Combination (TEC) versus
Paclitaxel/Carboplatin (TC) in the treatment of women with Advanced Ovarian Cancer |
55955
| A randomised trial in relapsed ovarian cancer: Early treatment based on CA 125
levels alone vs Delayed treatment based on conventional clinical indicators -
MRC OV05 and EORTC/GCCG 55955 |
55971
| Randomized Phase III study comparing upfront debulking surgery versus
neo-adjuvant chemotherapy in patients with Stage IIIc or IV epithelial
ovarian carcinoma. |
55962
| A randomized phase III trial for evaluation of usefullness of pelvic drains after
radical hysterectomy and node dissection (RHND) |
55954
| A randomized phase III study of chemotherapy and radiotherapy versus radiotherapy
alone as adjuvant treatment to patients with node positive stages Ib or IIa cervix
cancer (EO ORTC/NSGO/COSA/MRC intergroup trial) |
55951
| Taxol or Oxaliplatin in platinum-pretreated advanced ovarian cancer patients |
55931
| EORTC-NCIC-Scottish-Scandinavian-Intergroup phase III comparison of a combination of Taxol-platinum and a combination of cyclophosphamide-platinum chemotherapy in the treatment of advanced epithelial ovarian cancer |
55842
| Phase II trial of 4'-epiDoxorubicin in disseminated carcinoma of the uterine cervix |
55923
| Phase II study of Cisplatin, Doxorubicin, and Ifosfamide in carcinosarcoma (malignant mixed mesodermal tumors) of the female genital tract |
55904
| Phase III study to evaluate platinum based chemotherapy as an adjuvant to surgery in early ovarian cancer patients |
55883
| Phase II study of Navelbine in patients with advanced and/or recurrent cervical carcinoma |
55892
| Phase II study of high dose Epirubicin in patients with advanced ovarian carcinoma |
55891
| Phase II study of etoposide in patients with recurrent or advanced granulosa-theca cell tumor of the ovary |
55881
| Phase II trial of Fotemustine (S 100360) in patients with advanced ovarian carcinoma |
55882
| PHASE II TRIAL OF FLUTAMIDE IN PATIENTS WITH ADVANCED OVARIAN CARCINOMA. |
55872
| Randomized phase II protocol to study adriamycin/Cisplatin in combination and adriamycin alone in patients with advanced and/or recurrent endometrial carcinoma |
55874
| Phase III study to evaluate the role of adjuvant radiotherapy in the treatment of uterine sarcomas stages I and II |
55875
| Intraperitoneal Cisplatin versus no further treatment: A phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based induction chemotherapy and cytoreductive surgery |
55876
| Phase II study of D-TRP-6-LHRH (decapeptyl) in patients with advanced ovarian carcinoma |
55871
| Phase II study of bleomycin, Methotrexate and CCNU in locally advanced, radically inoperable squamous cell carcinoma of the vulva |
55873
| Randomized phase II protocol to study cyclophosphamide or Ifosfamide in patients with advanced and/or recurrent endometrial carcinoma |
55865
| Phase III study for the treatment of ovarian cancer FIGO stages IIB and C, III and IV |
55863
| Randomized phase III trial of vindesine, Cisplatin, bleomycin and mitomycin-C (BEMP) versus Cisplatin (P) in disseminated squamous cell carcinoma of the uterine cervix |
55862
| Phase II study of a combination of cis-diammine-dichloro-platinum, vinblastine, and bleomycin in patients with recurrent or advanced dysgerminoma |
55856
| Phase II trial for intraperitoneal cisplatin in ovarian cancer FIGO III, IV minimal residual disease after chemotherapy and cytoreductive surgery |
55857
| Phase II trial of 5-aza-2'-deoxycytidine in patients with advanced or recurrent squamous cell carcinoma of the uterine cervix |
55854
| Phase II Randomized Chemotherapy Trial of CHIP vs CACP in Patients with Advanced Ovarian Cancer Refractory or Recurrent After First-Line Chemotherapy with CBDCA (Summary Last Modified 05/88) |
55853
| Phase II trial of carboplatin in advanced/recurrent endometrial carcinoma |
55852
| Phase II trial of a combination of Cyclophosphamide, Adriamycin, and Cisplatin (CAP) in advanced tuba carcinoma |
55851
| Phase II trial of a combination of vindesine, Cisplatin, bleomycin, and mitomycin-C (BEMP) in disseminated squamous cell carcinoma of the uterine cervix |
55843
| Phase II trial of a combination of cis-diammine-dichloro-platinum, vinblastine, and bleomycin in patients with recurrent or advanced granulosa-theca cell tumors of the ovary |
55839
| Phase II Chemotherapy with Mitoxantrone for Recurrent and/or Disseminated Endometrial Carcinoma |
55112
| Efficacy of aromatase inhibitors in primary advanced or recurrent endometrial stromal sarcoma : a phase II trial. |
55831
| Phase II study of bleomycin, methotrexate, and CCNU in advanced radically inoperable squamous cell carcinoma of the vulva |
55832
| Phase II study of mitomycin C - cisplatin in disseminated squamous cell carcinoma of the uterine cervix |
55835
| Phase II study of bromocriptine in the treatment of patients with carcinoma of the cervix |
55837
| Phase II study of 4'-deoxydoxorubicin in patients with advanced ovarian carcinoma |
55838
| Phase II study of tamoxifen in patients with advanced ovarian carcinoma |
55833
| Phase II study of cyclophosphamide, adriamycin and cis-diammine-dichloroplatinum (II) in disseminated endometrial carcinoma. |
55836
| Phase III study for the treatment of ovarian cancer FIGO IIb, c, III and IV. |
55845
| Phase II study of 1, 2, 4-triglycidylurazol (TGU) in patients with advanced ovarian carcinoma |
55858
| Phase II trial of high dose megestrol acetate in patients with advanced ovarian carcinoma |
55804
| Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer |
55811
| Phase II trial of vindesine in disseminated cancer of the uterine cervix |
55774
| Treatment of stage III and IV ovarian cancer with VP-16 213 (phase II study) |
55861
| Phase II study of mitozolomide in patients with advanced ovarian carcinoma |
55773
| Phase III trial of melphalan versus adriamycin plus CTX in stage IC, IIB, III and IV epithelial carcinoma of the ovary |
55775
| Phase II study of bleomycin infusion in advanced ovarian cancer |
55781
| Phase III trial of cyclophosphamide plus adriamycin versus cyclophosphamide plus adriamycin plus cisplatin in stage III and IV epithelial carcinoma of the ovary |
55802
| Phase II trial of vincristine, bleomycin, mitomycin C and cisplatin in disseminated squamous cell carcinoma of the uterine cervix |
55803
| Phase II trial of PALA in advanced ovarian cancer |
55771
| Randomized controlled clinical trial (in progress jointly with the Ovary Group) for the treatment of patients with stages IA 2, IB, IIA: surgery followed by radiotherapy to the pelvis followed by a randomization between melphalan maintenance chemotherapy (12 months) and no further treatment |
55772
| Randomized controlled clinical trial (in progress jointly with the Ovary Group) for the treatment of patients with stages IC, IIB, III (< 2 cm residual disease) : surgery followed by a randomization between abdominal pelvic irradiation and no irradiation; both followed by melphalan maintenance chemotherapy (12 months) |
55116
| A Phase III Randomized Trial of Gemcitabine plus Docetaxel followed by Doxorubicin v. observation for uterus-limited, High Grade Uterine Leiomyosarcoma |